BERLIN (Reuters) -Germany will promote Moderna for Germans seeking booster shots as high demand for the BioNTech/Pfizer vaccine risks depleting stocks and derailing efforts to tame a fourth wave of the pandemic, Health Minister Jens Spahn said on Monday.
Spahn warned during a news conference that some 16 million Moderna doses could expire in the first quarter of next year if unused, adding that some experts see Moderna as the “Rolls-Royce” of vaccines with BioNTech the “Mercedes”.
“Unfortunately the impression is we will insist on Moderna only to avoid the expiry of those vaccines in the first quarter of 2022,” said Spahn.
“This is an important aspect but it is not the decisive one. What’s crucial is that our BioNTech stock is emptying so fast that coming next week we won’t be able to deliver more than 2-3 million doses a week.”
Germany is struggling to rein in a fourth wave driven mainly by the more infectious Delta variant that has pushed infection rates to record highs across Europe.
The Robert Koch Institute reported on Monday that the 7-day infection count rose to 386.5 per 100,000 citizens, or 30,643 in total over 24 hours, 7,000 more than a week ago. More than 60 people died of the virus in the past 24 hours.
Germany’s 16 states, whose remit includes public health, are trying to break the wave by rolling out booster shots, appealing to the unvaccinated to take the shot, and imposing a patch-work of restrictions.
The eastern state of Saxony and the southern state of Bavaria have cancelled Christmas markets which were set to open this week. Across Germany, most businesses remain open to those who are either vaccinated or recovered as authorities try to break resistance to getting a shot in a country where the vaccination rate stands at 68%, compared to almost 80% in Spain.
Spahn said that booster shots would take at least two weeks to start flattening the curve of infections and said only contact restrictions could help in the shorter term.
Spahn sought to allay concerns of vaccine shortages as Germany has a combined 50 million doses from BioNTech and Moderna available until the end of the year, enough for first and second shots as well as boosters.
(Additional reporting by Patricia Weiss in Frankfurt; Editing by Nick Macfie)